Methylnaltrexone Antagonizes Opioid-Mediated Enhancement of HIV Infection of Human Blood Mononuclear Phagocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 3, 2003, Pages 1158-1162

  Ho, Wen Zhe ^a   Guo, Chang Jiang ^a   Yuan, Chun Su ^b   Douglas, Steven D ^a   Moss, Jonathan ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; BETA CHEMOKINE; OPIATE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONSTIPATION; DRUG ABUSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE ACTIVATION; MONONUCLEAR PHAGOCYTE; NEUROMODULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RISK BENEFIT ANALYSIS; STRAIN DIFFERENCE; VIRUS ENVELOPE; VIRUS REPLICATION;

CELLS, CULTURED; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MONOCYTES; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5;

EID: 0344304773     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.056697     Document Type: Article

References (29)

1. Alcabes P and Friedland G (1995) Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 20:1467-1479.
2. Chao CC, Gekker G, Hu S, Kravitz F, and Peterson PK (1998) Kappa-opioid potentiation of tumor necrosis factor-alpha-induced anti-HIV-1 activity in acutely infected human brain cell cultures. Biochem Pharmacol 56:397-404.
3. Chao CC, Gekker G, Hu S, Sheng WS, Portoghese PS, and Peterson PK (1995) Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by dynorphin. Biochem Pharmacol 50:715-722.
4. Chao CC, Hu S, Gekker G, Lokensgard JR, Heyes MP, and Peterson PK (2000) U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression. Neuropharmacology 39:150-160
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, DiMarzio P, Marmon S, Sutton RE, Hill CM, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature (Lond) 381:661-666.
6. Donahoe RM and Falek A (1988) Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS. Adv Biochem Psychopharmacol 44:145-158.
7. Guo CJ, Li Y, Tian S, Wang X, Douglas SD, and Ho WZ (2002) Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 50:435-442.
8. Hassan NF, Campbell DE, and Douglas SD (1986) Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods 95:273-276.
9. Kilby JM and Eron JJ (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 3 48:2228-2238.
10. Kulkarni-Narla A, Walcheck B, and Brown DR (2001) Opioid receptors on bone marrow neutrophils modulate chemotaxis and CD11b/CD18 expression. Eur J Pharmacol 414:289-294.
11. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, and Ho WZ (2002) Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 185:118-122.
12. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, and Rogers TJ (2001) Opioids, opioid receptors and the immune response. Drug Alcohol Depend 62:111-123.
13. Miyagi T, Chuang LF, Doi RH, Carlos MP, Torres JV, and Chuang RY (2000) Morphine induces gene expression of CCR5 in human CEMx174 lymphocytes. J Biol Chem 275:31305-31310.
14. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, and Chadha KC (1997) Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 4:127-132.
15. Peterson PK, Gekker G, Hu S, Anderson WR, Kravitz F, Portoghese PS, Balfour HH Jr, and Chao CC (1994) Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. J Neuroimmunol 50:167-175.
16. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, and Balfour HH Jr (1990) Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 4:869-873.
17. Risdahl JM, Khanna KV, Peterson PK, and Molitor TW (1998) Opiates and infection. J Neuroimmunol 83:4-18.
18. Rogers TJ and Peterson PK (2003) Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24:116-121.
19. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, and Kurz A (2001) Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 345:935-940.
20. Thomas J, Portenoy R, Moehl M, Von Gunten C, Thielemann P, Stambler N, Tran D, Galasso F, and Israel R (2003) A phase II randomized dose-finding trial of methylnaltrexone for the relief of opioid-induced constipation in hospice patients (Abstract). Proc Am Soc Clin Oncol 22:2933.
21. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, and Martin MA (1988) In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62:139-147.
22. Yuan CS, Doshan H, O'Connor M, Maleckar SA, Israel R, and Moss J (2003) Methylnaltrexone reduces oral-cecal transit time in humans (Abstract). Dig Dis Week A824.
23. Yuan CS and Foss JF (1999) Gastric effects of methylnaltrexone on mu, kappa and delta opioid agonists induced brainstem unitary responses, Neuropharmacology 38:425-432.
24. Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, and Moss J (2000b) Effects of enteric-coated methylnaltroxone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 67:398-404.
25. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, and Roizen MF (2000a) Methylnaltroxone for reversal of constipation due to chronic methadone use: a randomized controlled trial. J Am Med Assoc 283:367-372.
26. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, and Moss J (1998) Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 52:161-165.
27. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, and Moss J (1996) Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther 59:469-475.
28. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, and Moss J (1997) The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61:467-475.
29. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, and Osinski J (2002) Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300:118-123.